Mysoline (primidone) NDC 66490-691

NDC codes

FDA NDC Directory

Product NDC (as listed)66490-691Labeler and product segments. Claims need a package NDC.

Product NDC at billing width66490-0691Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
66490-691-10	66490069110	100 TABLET in 1 BOTTLE (66490-691-10)Marketed from Jun 24, 2009

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Mysoline
Generic name (nonproprietary): primidone
Active ingredients: Primidone — 250 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Bausch Health US, LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 009170
Marketing start: Jun 24, 2009
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 66490-691_8604870a-4144-4f14-8720-616b25257be6SPL ID 8604870a-4144-4f14-8720-616b25257be6SPL set ID af593171-dabb-4ea3-b44c-89ed457b2c46RxCUI 96304, 198150, 201747, 207478UNII 13AFD7670QUPC 0366490691105
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N466490069110 followed by a unit qualifier and the quantity

Package 66490-0691-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 10, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE MYSOLINE, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 009170

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 009170
Product	Strength	Form · route	Labeler	Product NDC
Mysolineprimidone	Primidone 50 mg/1	TabletOral	Bausch Health US, LLC	66490-690